BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20600034)

  • 1. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
    Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
    Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
    Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
    Huang L; Zhu C; Sun Y; Xie G; Mackenzie GG; Qiao G; Komninou D; Rigas B
    Carcinogenesis; 2010 Nov; 31(11):1982-90. PubMed ID: 20627873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
    Xie G; Nie T; Mackenzie GG; Sun Y; Huang L; Ouyang N; Alston N; Zhu C; Murray OT; Constantinides PP; Kopelovich L; Rigas B
    Br J Pharmacol; 2012 Apr; 165(7):2152-66. PubMed ID: 21955327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.
    Huang L; Mackenzie G; Ouyang N; Sun Y; Xie G; Johnson F; Komninou D; Rigas B
    Br J Pharmacol; 2011 Apr; 162(7):1521-33. PubMed ID: 21175575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
    Zhu R; Cheng KW; Mackenzie G; Huang L; Sun Y; Xie G; Vrankova K; Constantinides PP; Rigas B
    Pharm Res; 2012 Nov; 29(11):3090-101. PubMed ID: 22723123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
    Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
    J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulindac activates NF-κB signaling in colon cancer cells.
    Mladenova D; Pangon L; Currey N; Ng I; Musgrove EA; Grey ST; Kohonen-Corish MR
    Cell Commun Signal; 2013 Oct; 11():73. PubMed ID: 24083678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
    Cheng KW; Mattheolabakis G; Wong CC; Ouyang N; Huang L; Constantinides PP; Rigas B
    Int J Oncol; 2012 Oct; 41(4):1199-203. PubMed ID: 22842609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate.
    Murray OT; Wong CC; Vrankova K; Rigas B
    Int J Oncol; 2014 Feb; 44(2):521-9. PubMed ID: 24284479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.
    Agarwal B; Rao CV; Bhendwal S; Ramey WR; Shirin H; Reddy BS; Holt PR
    Gastroenterology; 1999 Oct; 117(4):838-47. PubMed ID: 10500066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
    Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
    Huang L; Mackenzie GG; Sun Y; Ouyang N; Xie G; Vrankova K; Komninou D; Rigas B
    Cancer Res; 2011 Dec; 71(24):7617-27. PubMed ID: 22025561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
    Kashfi K; Chattopadhyay M; Kodela R
    Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.
    Cheng KW; Wong CC; Alston N; Mackenzie GG; Huang L; Ouyang N; Xie G; Wiedmann T; Rigas B
    Mol Cancer Ther; 2013 Aug; 12(8):1417-28. PubMed ID: 23645590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
    Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
    Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
    Piazza GA; Alberts DS; Hixson LJ; Paranka NS; Li H; Finn T; Bogert C; Guillen JM; Brendel K; Gross PH; Sperl G; Ritchie J; Burt RW; Ellsworth L; Ahnen DJ; Pamukcu R
    Cancer Res; 1997 Jul; 57(14):2909-15. PubMed ID: 9230200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.
    Erdman SH; Ignatenko NA; Powell MB; Blohm-Mangone KA; Holubec H; Guillén-Rodriguez JM; Gerner EW
    Carcinogenesis; 1999 Sep; 20(9):1709-13. PubMed ID: 10469614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
    Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
    Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.